| AZD0120 / AstraZeneca |
| Recruiting | 1/2 | 20 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 07/23 | 07/23 | | |
NCT06235229: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 110 | RoW | GC012F | Gracell Biotechnologies Ltd. | Multiple Myeloma | 03/26 | 06/26 | | |
NCT06530849: A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus |
|
|
| Not yet recruiting | 1/2 | 118 | NA | GC012F Injection | Gracell Biotechnologies (Shanghai) Co., Ltd., AstraZeneca, Suzhou Gracell Biotechnologies Co., Ltd. | Systemic Lupus Erythematosus | 02/27 | 02/27 | | |
NCT05850234: A Study of GC012F, a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma |
|
|
| Recruiting | 1/2 | 71 | US | GC012F | Gracell Biopharmaceuticals, Inc. | Relapsed/ Refractory Multiple Myeloma | 03/26 | 06/26 | | |
NCT04617704: BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma |
|
|
| Not yet recruiting | 1 | 15 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 12/21 | 02/22 | | |
GBF002, NCT04236011: BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma |
|
|
| Recruiting | 1 | 15 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 07/22 | 12/22 | | |
NCT04412889: A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM |
|
|
| Not yet recruiting | 1 | 18 | RoW | BCMA/CD19 dual-target CAR-T cell immunotherapy | Hebei Yanda Ludaopei Hospital, Gracell Biotechnology Ltd. | Multiple Myeloma | 12/22 | 12/22 | | |
NCT05846347: Phase I Clinical Study of GC012F Injection in Treatment of Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 15 | RoW | GC012F injection, CD19-BCMA CAR-T cells | Zhejiang University, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T | 10/23 | 04/25 | | |
NCT05858684: Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection, CD19-BCMA CAR-T cells | RenJi Hospital, Gracell Biotechnology Shanghai Co., Ltd. | CAR-T Cell Therapy | 11/23 | 05/25 | | |
NCT05412329: Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma |
|
|
| Recruiting | 1 | 9 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 06/24 | 06/24 | | |
NCT06419166: An Exploratory Clinical Study of GC012F Injection for Refractory gMG |
|
|
| Not yet recruiting | 1 | 18 | RoW | GC012F injection | Zhejiang University, Gracell Biotechnologies (Shanghai) Co., Ltd. | Refractory Generalized Myasthenia Gravis | 06/27 | 10/27 | | |
NCT05840107: Study of FasT CAR-T GC012F Injection NDMM Patients |
|
|
| Recruiting | 1 | 18 | RoW | GC012F injection | Shanghai Changzheng Hospital, Gracell Biotechnology Shanghai Co., Ltd. | Multiple Myeloma | 09/25 | 09/25 | | |
ChiCTR1900027678: GC012F injection (BCMA/CD19 CAR-T) in the treatment of recurrent refractory BCMA+ multiple myeloma |
|
|
| Recruiting | N/A | 12 | | CD19/BCMA CAR-T therapy | The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University, Gracell Biotechnology Ltd. | BCMA+Multiple Myeloma | | | | |
ChiCTR2100047061: An early exploratory study of GC012F injection in the treatment of CD19 and/or BCMA positive relapsed or refractory B-cell non-Hodgkin's lymphoma |
|
|
| Recruiting | N/A | 12 | | GC012F treatment | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Gracell Biotechnologies | B-cell non-Hodgkin's lymphoma | | | | |
